The clinical utility of targeted NGS in neurodevelopmental
disorders: a case of a girl with pontocerebellar hypoplasia
caused by TSEN54 gene pathogenic variants

a 2020

The clinical utility of targeted NGS in neurodevelopmental disorders: a case of a girl with pontocerebellar hypoplasia caused by TSEN54 gene pathogenic variants

WAYHELOVÁ, Markéta; Vladimíra VALLOVÁ; Eva HLADÍLKOVÁ; Hana FILKOVÁ; Jan OPPELT et al.

Základní údaje

Originální název

The clinical utility of targeted NGS in neurodevelopmental disorders: a case of a girl with pontocerebellar hypoplasia caused by TSEN54 gene pathogenic variants

Autoři

WAYHELOVÁ, Markéta; Vladimíra VALLOVÁ; Eva HLADÍLKOVÁ; Hana FILKOVÁ; Jan OPPELT; Jana ŠOUKALOVÁ a Petr KUGLÍK

Vydání

ESHG 2020 - European Human Genetics Virtual Conference, 2020

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10603 Genetics and heredity

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.246

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14310/20:00116860

Organizační jednotka

Přírodovědecká fakulta

ISSN

UT WoS

000598482603153

Klíčová slova anglicky

neurodevelopmental disorders; NGS

Štítky

14314010

Změněno: 13. 5. 2021 17:48, Mgr. Markéta Wayhelová, Ph.D.

Anotace

V originále

Next-generation sequencing (NGS) techniques have become a powerful tool for the identification of the genetic causes of the heterogeneous conditions such as intellectual disabilities, multiple congenital anomalies and autism spectrum disorders. Here we present our first experience with targeted NGS approach using commercially available design SureSelect Inherited Disease (Agilent Technologies, Santa Clara, CA, USA) containing more than 2700 genes known to cause inherited disorders. We report on a case of 9-year-old boy with a diagnosis of severe intellectual disability related to early myoclonic encephalopathy. This patient was examined according to our investigatory algorithm, from G-banding karyotype (46,XY) to array-CGH on oligonucleotide DNA microarrays (Agilent Technologies, Santa Clara, CA, USA) followed by confirmative targeted quantitative PCR and FISH. We detected a de novo copy-number gain of 18q21.23 (539 kb), however, it could not explain his pathological phenotype. Consequently this patient was included in our pilot study using targeted NGS with pre-designed gene panel SureSelect Inherited disease and Illumina MiSeq. We detected de novo heterozygous missense genetic variant in SCN2A gene, resulting in the amino acid residue change from alanine to valine at position 263 (p.Ala263Val). This variant had been previously described as definitely pathogenic in patients with Otahara syndrome. This case has proved the usefulness and effectivity of our molecular diagnostics algorithm enhanced by NGS approaches leading to higher diagnostic yield of heterogeneous genetic conditions. This study was supported by IP 2016 (University Hospital, Brno) and the Specific Research Fund (Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno).

Návaznosti

MUNI/A/1127/2019, interní kód MU

Název: Podpora výzkumné činnosti studentů molekulární biologie a genetiky 8 (Akronym: MBG 8)

Investor: Masarykova univerzita, Podpora výzkumné činnosti studentů molekulární biologie a genetiky 8, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

WAYHELOVÁ, Markéta; Vladimíra VALLOVÁ; Eva HLADÍLKOVÁ; Hana FILKOVÁ; Jan OPPELT; Jana ŠOUKALOVÁ a Petr KUGLÍK. The clinical utility of targeted NGS in neurodevelopmental disorders: a case of a girl with pontocerebellar hypoplasia caused by TSEN54 gene pathogenic variants. In ESHG 2020 - European Human Genetics Virtual Conference. 2020. ISSN 1018-4813.

@proceedings{1689796,
   author = {Wayhelová, Markéta and Vallová, Vladimíra and Hladílková, Eva and Filková, Hana and Oppelt, Jan and Šoukalová, Jana and Kuglík, Petr},
   booktitle = {ESHG 2020 - European Human Genetics Virtual Conference},
   keywords = {neurodevelopmental disorders; NGS},
   language = {eng},
   title = {The clinical utility of targeted NGS in neurodevelopmental disorders: a case of a girl with pontocerebellar hypoplasia caused by TSEN54 gene pathogenic variants},
   year = {2020}
}

TY  - CONF
ID  - 1689796
AU  - Wayhelová, Markéta - Vallová, Vladimíra - Hladílková, Eva - Filková, Hana - Oppelt, Jan - Šoukalová, Jana - Kuglík, Petr
PY  - 2020
TI  - The clinical utility of targeted NGS in neurodevelopmental disorders: a case of a girl with pontocerebellar hypoplasia caused by TSEN54 gene pathogenic variants
KW  - neurodevelopmental disorders
KW  - NGS
N2  - Next-generation sequencing (NGS) techniques have become a powerful tool for the identification of the genetic causes of the heterogeneous conditions such as intellectual disabilities, multiple congenital anomalies and autism spectrum disorders. Here we present our first experience with targeted NGS approach using commercially available design SureSelect Inherited Disease (Agilent Technologies, Santa Clara, CA, USA) containing more than 2700 genes known to cause inherited disorders. We report on a case of 9-year-old boy with a diagnosis of severe intellectual disability related to early myoclonic encephalopathy. This patient was examined according to our investigatory algorithm, from G-banding karyotype (46,XY) to array-CGH on oligonucleotide DNA microarrays (Agilent Technologies, Santa Clara, CA, USA) followed by confirmative targeted quantitative PCR and FISH. We detected a de novo copy-number gain of 18q21.23 (539 kb), however, it could not explain his pathological phenotype. Consequently this patient was included in our pilot study using targeted NGS with pre-designed gene panel SureSelect Inherited disease and Illumina MiSeq. We detected de novo heterozygous missense genetic variant in SCN2A gene, resulting in the amino acid residue change from alanine to valine at position 263 (p.Ala263Val). This variant had been previously described as definitely pathogenic in patients with Otahara syndrome. This case has proved the usefulness and effectivity of our molecular diagnostics algorithm enhanced by NGS approaches leading to higher diagnostic yield of heterogeneous genetic conditions. This study was supported by IP 2016 (University Hospital, Brno) and the Specific Research Fund (Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno).
ER  -

WAYHELOVÁ, Markéta; Vladimíra VALLOVÁ; Eva HLADÍLKOVÁ; Hana FILKOVÁ; Jan OPPELT; Jana ŠOUKALOVÁ a Petr KUGLÍK. The clinical utility of targeted NGS in neurodevelopmental disorders: a case of a girl with pontocerebellar hypoplasia caused by TSEN54 gene pathogenic variants. In \textit{ESHG 2020 - European Human Genetics Virtual Conference}. 2020. ISSN~1018-4813.

Přehled o publikaci